Number of Patients, Male	9
Number of Patients, Female	6
Stage	Refractory/advanced/metastatic
Age	Median (range): 62 (45–78) years
Performance Status: ECOG	0 — 20% 1 — 80% 2 — 0 3 — 0 Unknown — 0
Other	Median age, years (range)	62.0 (45–78)
	Male, n (%)	9 (60.0)
	ECOG performance status score, n (%)
	0	3 (20.0)
	1	12 (80.0)
	Any prior cancer‐related systemic therapy, n (%)	15 (100.0)
	Antineoplastic agents	15 (100.0)
	Platinum compounds	15 (100.0)
	Monoclonal antibodies	9 (60.0)
	Pyrimidine analogues	9 (60.0)
	Taxanes	8 (53.3)
	Combination of antineoplastic agents	1 (6.7)
	Other	2 (13.3)
	Immunosuppressants	2 (13.3)
	Any prior cancer‐related radiotherapy, n (%)	14 (93.3)